Adicet Bio Reports Lupus Remissions in CAR-T Trial, Avoiding Safety Issues Seen in Rivals
Adicet Bio reported that its off-the-shelf CAR-T therapy, prula-cel, induced remission in over half of lupus patients in a Phase 1 trial. The treatment showed a favorable safety profile with no severe inflammatory events, distinguishing it from rival autologous therapies that recently faced trial pauses due to fatalities.